Frontiers Health 2024

Our CEO, Sharon Cunningham will be speaking at Frontiers Health, one of the worlds leading global health innovation events, taking place October 17th – 18th at the Berlin Congress Center.

Shorla Oncology co-founders win EY Entrepreneurs of the Year award

Shorla Oncology develops and commercializes innovative oncology drugs, where existing treatments are limited, in shortage or inadequate.

Shorla Oncology Announces FDA Approval of IMKELDI (imatinib mesylate)

Shorla Oncology Announces U.S. Food and Drug Administration (FDA) Expanded Approval of JYLAMVO™ (methotrexate), an Oncology and Autoimmune Drug for Pediatric Indications

Shorla Oncology will be attending The (ACR) Convergence 2024 in Washington DC from Nov 14-19

Shorla Oncology at ASHP Mid Year 2024, New Orleans, Dec 8-12

Shorla, Protega Win Expanded Nods for Cancer/Autoimmune, Pain Therapies

FDA expands Jylamvo approval to include polyarticular juvenile idiopathic arthritis, ALL

FDA Expands Methotrexate Indication to Included Children With Acute Lymphoblastic Leukemia

LATEST NEWS